Tag Archive for: 225Ac
UPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/0 Comments/in Preclinical Research/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Mevrometostat Update: a New Phase 3 Trial for mCSPC July 1, 2025
- MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC June 30, 2025
- Newsletter 26/2025 June 29, 2025
- AlphaGenome: Another Incredible AI Tool for Biology June 27, 2025